Slow vs. rapid steroid taper with inebilizumab for NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial is for people with NMOSD who have recently had an attack. It compares two ways of slowly reducing steroid treatment while also receiving an experimental drug called inebilizumab, to see which approach helps prevent future attacks better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of NMOSD.
- You must test positive for AQP4 antibodies in your blood.
- You must have had an attack within the last month, and be currently on a daily steroid dose of 60 mg prednisone (or equivalent).
- You cannot be pregnant, breastfeeding, or planning pregnancy during the study.
- You cannot have serious active infections like tuberculosis, hepatitis B or C, or HIV, or other conditions like severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
This trial tests a new drug called inectolizumab combined with steroids for people having their first attack of NMOSD, a rare autoimmune disease that can cause vision loss and paralysis. The goal is to see if this combination is safe and helps reduce symptoms.
This trial studies whether inebilizumab can reduce illness activity in children with neuromyelitis optica spectrum disorder (NMOSD), a condition that can cause attacks affecting the eyes and spinal cord. It focuses on kids who have had recent relapses, meaning symptoms came back or worsened.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Hear when a new Neuromyelitis Optica Spectrum Disorders (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.